Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Reck, M Kerr, KM Grohe, C Manegold, C Pavlakis, N Paz-Ares, L Huber, RM Popat, S Thatcher, Nick Park, K
Reck, M
Kerr, KM
Grohe, C
Manegold, C
Pavlakis, N
Paz-Ares, L
Huber, RM
Popat, S
Thatcher, Nick
Park, K
Citations
Altmetric:
Abstract
Abstract
A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression. Based on a review of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression within <6-9 months of first-line treatment initiation.
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Reck M, Kerr KM, Grohe C, Manegold C, Pavlakis N, Paz-Ares L, et al. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity? Future Oncol. 2019 Feb 13.